focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,775.00
Bid: 1,771.00
Ask: 1,771.50
Change: -8.50 (-0.48%)
Spread: 0.50 (0.028%)
Open: 1,773.50
High: 1,779.00
Low: 1,764.50
Prev. Close: 1,783.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LIVE MARKETS-A "healthier rally" ahead?

Tue, 27th Mar 2018 11:57

* European stocks rise 1.4 pct * Wall Street, Asia surged on China-U.S. trade talks March 27 - Welcome to the home for real-time coverage of European equity markets brought toyou by Reuters stocks reporters and anchored today by Helen Reid. Reach her on Messenger toshare your thoughts on market moves: helen.reid.thomsonreuters.com@reuters.net A "HEALTHIER RALLY" AHEAD? (1052 GMT) We've had a "healthy" correction, but could the recent sell-off lead to a "healthy" rally? Barclays' equity derivative strategists see the possibility of a trade war keeping themarket on edge, which they say would allow some of the "excessive exuberance" to abate. Theypoint to a cooling in equity market valuations since the recent sell-off (see Barclays' chartsbelow) and sentiment among retail investors moderating. "In one sense, we view this as a healthy development, given it would provide an outlet forsome of the excess exuberance," say Barclays' strategists in a note. One thing to watch is how fast volatility normalises. Barclays notes that if this isgradual, it would be a sign that market sentiment was cautious and herald a return to "the“normal” grinding rally". "If equities do not recover sharply, we believe valuations have a better chance ofnormalising, which would set the stage for a healthier subsequent rally," Barclays concludes. (Kit Rees) ***** KEEPING TABS ON THE S&P'S 200-DAY MOVING AVERAGE (1005 GMT) Investors are increasingly looking at the S&P 500's 200-day moving average,especially after the two big sell-offs that roiled markets this year saw the bears surrender tothe bulls just when the U.S. benchmark index hit that level. The S&P fell more than 6 percent last week to end a tick above the 200-day average, but onMonday it staged a powerful bounce, indicating how crucial that level has become for the market. Going forward, any breach below it may well be seen as a negative signal and JCI Capitalfund manager Alessandro Balsotti believes that from now on investors will be monitoring it evenmore "religiously". And what about Europe? Well it's a different story: the STOXX 600 has been tradingbelow the 200-day average since early February. (Danilo Masoni) ***** SHARES SHRUG OFF WEAK EUROPEAN DATA BUT "PEAK GROWTH" NARRATIVE BUILDS (0950 GMT) Economic sentiment in the euro zone slipped for a third month in a row in March as managersin manufacturing, services and retail became slightly less optimistic, European Commission datajust showed. But stocks are taking this in their stride and have even accelerated their risefrom 1.2 percent to 1.5 percent since the data was published. A whole bunch of research this morning ahead of the publication noted, like DNB's dailynote, that "Eurozone macro data surprises have been more negative than positive recently" andthat "growth is strong, but no longer accelerating". For CMC Markets, "the beginning of possible micro fissures in the European growth story"and "momentum indicators ... flashing warning signs" may be an explanation as to why Europeanmarkets are having a hard time keeping up with their U.S. counterparts. In a strategy note on European equities this morning, HSBC said that its "economics team'sview of GDP growth momentum fading through the course of this year" backed investing in longerduration fixed income and in stocks with higher dividend yield for their "defensive attributes". On the trading floor however the consensus seems to be that the euro zone's economic healthstill backs an optimistic view of its shares. There can be "a lot of noise in macro data in thenear-term", Chris Dyer, director of global equity at Eaton Vance just told us. "Generally we think the European economy is on a good footing", Dyer, who is overweightEuropean equities, said, adding that the weakness in economic data will only become a concern ifit continues. Here's a chart by DNB showing the loss of growth momentum in Europe: (Helen Reid and Julien Ponthus) ***** OPENING SNAPSHOT: EUROPEAN STOCKS BOUNCE (0727 GMT) European shares are joining in a global relief rally in risk assets as trade tensions ease.Sectors which were hit hardest over the past few sessions, such as autos, basicresources and tech, are the biggest gainers early on. The biggest individual mover so far is France's Casino, which has jumped around 6percent after its Monoprix chain agreed to sell products via Amazon. This shows just how crucialit is for companies to demonstrate that they are keeping up with the times and exploring onlineopportunities. Regarding the spreadbetters and ESMA's restrictions on CFDs, it's a mixed bag following adecidedly negative start, with IG down slightly but both CMC and Plus500 making gains. Here's your opening snapshot: (Kit Rees) ***** WHAT'S ON THE RADAR FOR THE OPEN (0649 GMT) European stocks are set to surge with futures climbing 1.4 to 2.2 percent across the majorbenchmarks, riding the wave of rising equities worldwide after Wall Street indices had theirstrongest day in years as investors bet on a trade war détente. Retail stocks will be ones to watch after French supermarket group Casino struck a deal withAmazon to make groceries from its Monoprix chain of stores available on Amazon’s Prime Nowservice to Parisian customers this year. The partnership extends Amazon’s reach into the European grocery market, and while Casinoshares are seen rising 3 to 5 percent, the news could shake investors’ confidence in retailnames that are more behind the curve. In M&A news, GlaxoSmithKline shares are expected to rise 3 to 4 percent after the pharmacompany announced it was buying out Novartis’ stake in their consumer healthcare joint venturefor $13 billion. Novartis is seen up 1 percent. Another corporate break-up story from Akzo Nobel which is to sell its Specialty Chemicalsbusiness for $12.6 billion to U.S. private equity firm Carlyle Group and Singapore’s GIC –ending the simplification effort which began as the paint maker sought to evade a takeover fromPPG in April 2017. Its shares are set to rise 2 to 4 percent. Spreadbetters such as IG Group, CMC Markets and Plus500 are seen down 2 percent premarketafter a move from European markets regulator ESMA to crack down on contract-for-difference (CFD)trades offered to retail clients. (Helen Reid) ***** MORNING HEADLINE ROUND-UP (0637 GMT) Here's a round-up of key headlines for European companies this morning - note the news thatCasino's Monoprix is going to be teaming up with Amazon to sell groceries on Prime Nowin Paris. Casino's shares are seen up as much as 5 percent premarket. GSK buys Novartis stake in consumer healthcare venture for $13 bln H&M Q1 pretax dives in line with expectations, flags more markdowns Deutsche Bank seeks to replace CEO with Goldman executive -report Amazon wins grocery foothold in France through Monoprix deal Galliford Try to raise 158 mln stg to cover Carillion project costs Nordex sees lower sales, margins as wind industry tightens Akzo Nobel to sell unit to Carlyle, GIC for 10.1 bln euros (Kit Rees) ***** EUROPEAN STOCK FUTURES SURGE (0610 GMT) Futures for the major European stock markets have opened sharply higher, rising 1.1 to 1.8percent with the DAX in the lead, as investors place bets on a strong bounce at the open. Meanwhile analysts are still mulling what caused the late-afternoon slump in sharesyesterday. Here's Peel Hunt strategist Ian Williams: "The trigger was not immediately obvious with neither further strength in the euro, or thelatest wave of Russian diplomatic expulsions, especially convincing reasons for such a move. Amore worrying interpretation is that investors may be taking advantage of even the most modestof rallies to lighten their equity exposure." If Williams is right we may see a volatile session today as well - but for the moment allsigns are pointing to a strong rebound for the European market. (Helen Reid) ***** BULLS TO KEEP THE UPPER HAND (0548 GMT) Goldman Sachs' Bear/Bull indicator is above 70%, a level normally associated with animminent bear market (see below). But the GS team led by Peter Oppenheimer reckons relativelyattractive equity valuations will protect markets from a big drawdown, at least for now. There's also a wide spread in the underlying variables behind the indicator: very low levelsof unemployment and strong growth momentum are normally accompanied with "tighter monetarypolicy, a flatter yield curve and rising core inflation," notes GS. "But these remain subduedand without these risks rising, the prospect of a recession and 'cyclical' bear market is low." Valuation meanwhile is becoming less of a risk, they add - the forward consensus PE for theMSCI AC World is back to its 1990 average and below its average excluding Tech stocks. Highvaluations are mostly confined to the U.S. market. Furthermore, free cash flow yields have increased along with P/E ratios, and the total cashreturn from equities (dividend yield + buyback yield) has risen in most markets. So the overall message from GS is: don't panic! The bulls will prevail, at least for now... (Helen Reid) ***** MORNING CALL: EUROPEAN STOCKS TO BOUNCE BACK STRONGLY(0520 GMT) Good morning and welcome to Live Markets. Risk appetite is back! European stocks are called to open strongly higher today after a weakclose yesterday. They're being pushed up by the equities rally on Wall Street and in Asiaovernight greeting news that the U.S. and China are holding behind-the-scenes trade talks. White House officials are asking China to cut tariffs on imported cars, allow foreignmajority ownership of financial services firms and buy more U.S.-made semiconductors, accordingto a person familiar with the discussions. Asian shares bounced back overnight with the Nikkei up 1.7 percent and Chinese blue-chipsgaining 1.2 percent. The gains came after a stellar session on Wall Street with the Dowdelivering its third-biggest point gain ever, jumping 2.8 percent, while the S&P 500 gained 2.7percent and the Nasdaq surged up 3.3 percent. A negative currency effect could weigh on European stocks today, though, with the euro stillnear the six-week high against the dollar it touched yesterday. It had its biggest one-daypercentage gain since June 2017 yesterday. Spreadbetters call the DAX 183 points higher at 11,971, the CAC 40 up 60 points at 5,127,and the FTSE 100 78 points higher at 6,966. (Helen Reid) ***** (Reporting by Helen Reid, Danilo Masoni, Julien Ponthus and Kit Rees)
More News
17 Jan 2024 07:31

GSK raises $1.24 bln from latest Haleon stake sale

Jan 17 (Reuters) - GSK has raised 978 million pounds ($1.24 billion) from a discounted sale of a stake in its spun-off consumer healthcare business Haleon, the British drugmaker said on Wednesday.

Read more
16 Jan 2024 17:04

GSK to sell GBP1 billion worth of Haleon shares as trims stake again

(Alliance News) - GSK PLC on Tuesday said it intends to sell around GBP1.00 billion worth of shares in Haleon PLC, as it continues to reduce its shareholding in the Weybridge, Surrey-based consumer healthcare spin-off.

Read more
16 Jan 2024 09:14

LONDON BROKER RATINGS: UBS raises GSK and cuts AstraZeneca

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
16 Jan 2024 08:15

UBS downgrades AstraZeneca to 'sell'

(Sharecast News) - UBS has downgraded AstraZeneca and upgraded rival GSK as part of its latest review of the European pharmaceutical sector.

Read more
16 Jan 2024 07:37

LONDON BRIEFING: UK jobless rate sticks at 4.2% but pay growth slows

(Alliance News) - Stocks in London are called to open lower on Tuesday, following data showing that the UK jobless rate was unchanged at 4.2% as pay growth slowed.

Read more
15 Jan 2024 08:42

Zantac fallout unfairly weighing on GSK, says Shore Capital

(Sharecast News) - Shore Capital has raised its target price and maintained a positive stance on biopharma giant GSK, saying that worries about the potential cost of Zantac litigation are unfairly weighing on the stock.

Read more
10 Jan 2024 09:35

LONDON BROKER RATINGS: BofA cuts Ashtead; UBS likes 3i Group

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
10 Jan 2024 08:25

GSK says Nucala gets green light in China for asthma treatment

(Alliance News) - GSK PLC on Wednesday said Nucala has been approved in China for the treatment of severe asthma.

Read more
10 Jan 2024 07:22

GSK's Nucala gets fresh approval in China

(Sharecast News) - GSK announced on Wednesday that the China National Medical Products Administration (NMPA) has granted approval for 'Nucala', or mepolizumab, as an add-on maintenance treatment for severe eosinophilic asthma in adults and adolescents aged 12 years and older.

Read more
9 Jan 2024 16:22

London close: Stocks finish red after choppy session

(Sharecast News) - London stocks had turned back into the red by the close on Tuesday, with recruitment firms and asset managers pacing the declines after some disappointing corporate updates.

Read more
9 Jan 2024 08:03

TOP NEWS: GSK to buy Aiolos Bio for up to USD1.4 billion

(Alliance News) - GSK PLC on Tuesday said it will acquire asthma drug developer Aiolos Bio Inc for USD1 billion upfront, as well as up to USD400 million in certain success-based milestone payments.

Read more
9 Jan 2024 07:16

GSK buys respiratory drug maker Aiolos for $1bn

(Sharecast News) - GSK said it was buying Aiolos, a clinical-stage biopharmaceutical company focused on treatment of respiratory and inflammatory conditions, for up to $1.4bn (£1.1bn).

Read more
8 Jan 2024 23:39

Pfizer to remain aggressive on obesity market after setback

NEW YORK, Jan 8 (Reuters) - Pfizer will remain aggressive in trying to break into the lucrative obesity market, even after dropping a high profile weight-loss drug candidate late last year due to strong side effects, Chief Executive Albert Bourla said on Monday.

Read more
8 Jan 2024 23:00

Pfizer to remain aggressive on obesity market after setback

NEW YORK, Jan 8 (Reuters) - Pfizer will remain aggressive in trying to break into the lucrative obesity market, even after dropping a high profile weight-loss drug candidate late last year due to strong side effects, Chief Executive Albert Bourla said on Monday.

Read more
8 Jan 2024 19:02

Moderna says it hit its 2023 COVID vaccine sales goal

Jan 8 (Reuters) - Moderna on Monday said its 2023 COVID vaccine sales would be around $6.7 billion, coming in above the lower end of its full-year forecast, and reiterated its goal of returning to sales growth in 2025.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.